Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Glucose tolerance test, Maternal exposure during pregnancy, Pregnancy test, Ultrasound antenatal screen normal, Vaccination site pain
Clinical narrative: pain at injection site with first dose.; Maternal exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) and VACCINATION SITE PAIN (pain at injection site with first dose.) in a 34-year-old female patient (gravida 3, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (2 drinks a week), Ehlers-Danlos syndrome, Postural orthostatic tachycardia syndrome and Spontaneous abortion. Concurrent medical conditions included Drug allergy (Forteo (teriparatide)), Fruit allergy (Pomegranate.), Fragrance sensitivity (Fragrance.), Polyneuropathy and Sleep apnea (Complex sleep apnea.). Concomitant products included LEVOTHYROXINE from 15-Jul-2021 to an unknown date for Hypothyroidism, ONDANSETRON and DOXYLAMINE SUCCINATE, PYRIDOXINE HYDROCHLORIDE (BONJESTA) for Nausea, ACETYLSALICYLIC ACID (ASPIRIN (E.C.)), MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]), CALCIUM, DOXYLAMINE, DOCUSATE SODIUM (COLACE), FAMOTIDINE, SERTRALINE, VITAMIN D3, MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) and MAGNESIUM for an unknown indication.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 21-May-2020 and the estimated date of delivery was 24-Feb-2021. On 08-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy). On an unknown date, the patient experienced VACCINATION SITE PAIN (pain at injection site with first dose.). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirty-third week of the pregnancy. The vaginal delivery occurred on 12-Feb-2021, which was reported as Full-term. For neonate 1, The outcome was reported as Delivered NOS. On 08-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) had resolved. At the time of the report, VACCINATION SITE PAIN (pain at injection site with first dose.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Aug-2020, Ultrasound antenatal screen normal: normal (normal) normal( week u/s )  (MFM OB every 1-2 weeks). On 17-Jun-2021, Pregnancy test: positive (Positive) Positive. On an unknown date, Glucose tolerance test: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Mother had history of sub fertility 2 cycles of Femara April and May 2020.  Date of positive pregnancy test:17-Jun-2020.  Estimated due date:24-Feb-2021.  Patient had allergy to seminal plasma.  No treatment medication were provided.  Pregnancy history:  Pregnancy date: Feb-2017, Outcome: Spontaneous abortion. Pregnancy date: Mar-2020, Outcome: Spontaneous abortion.   This case was linked to MOD-2021-259303 (Parent-Child Link). This case was linked to MOD-2021-259284 (Patient Link).   See case MOD-2021-259303 for details regarding the child case.  Most recent FOLLOW-UP information incorporated above includes: On 18-Jul-2021: Patient demographics added, pregnancy details added, medical history added, lab data added, concomitant added.